vs

Side-by-side financial comparison of CIVISTA BANCSHARES, INC. (CIVB) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

RIGEL PHARMACEUTICALS INC is the larger business by last-quarter revenue ($69.8M vs $47.3M, roughly 1.5× CIVISTA BANCSHARES, INC.). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs 31.7%, a 352.3% gap on every dollar of revenue. Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 11.3%).

Civista Bancshares, Inc. is a US-based bank holding company operating primarily across the Midwest region. It provides a full suite of personal and commercial banking services including deposit accounts, mortgage, consumer and commercial lending products, as well as wealth management solutions, serving retail consumers, small and medium-sized local businesses and community client segments.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

CIVB vs RIGL — Head-to-Head

Bigger by revenue
RIGL
RIGL
1.5× larger
RIGL
$69.8M
$47.3M
CIVB
Higher net margin
RIGL
RIGL
352.3% more per $
RIGL
384.0%
31.7%
CIVB
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
11.3%
CIVB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CIVB
CIVB
RIGL
RIGL
Revenue
$47.3M
$69.8M
Net Profit
$15.0M
$268.1M
Gross Margin
91.5%
Operating Margin
33.2%
Net Margin
31.7%
384.0%
Revenue YoY
21.2%
Net Profit YoY
47.4%
1769.2%
EPS (diluted)
$0.72
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CIVB
CIVB
RIGL
RIGL
Q1 26
$47.3M
Q4 25
$46.3M
$69.8M
Q3 25
$44.2M
$69.5M
Q2 25
$41.4M
$101.7M
Q1 25
$40.6M
$53.3M
Q4 24
$40.4M
$57.6M
Q3 24
$39.3M
$55.3M
Q2 24
$38.1M
$36.8M
Net Profit
CIVB
CIVB
RIGL
RIGL
Q1 26
$15.0M
Q4 25
$268.1M
Q3 25
$12.8M
$27.9M
Q2 25
$11.0M
$59.6M
Q1 25
$10.2M
$11.4M
Q4 24
$14.3M
Q3 24
$8.4M
$12.4M
Q2 24
$7.1M
$-1.0M
Gross Margin
CIVB
CIVB
RIGL
RIGL
Q1 26
Q4 25
91.5%
Q3 25
93.2%
Q2 25
95.6%
Q1 25
91.7%
Q4 24
89.9%
Q3 24
85.5%
Q2 24
92.4%
Operating Margin
CIVB
CIVB
RIGL
RIGL
Q1 26
Q4 25
31.8%
33.2%
Q3 25
35.4%
40.9%
Q2 25
31.1%
60.1%
Q1 25
29.4%
23.9%
Q4 24
28.2%
28.9%
Q3 24
25.2%
25.4%
Q2 24
21.2%
1.2%
Net Margin
CIVB
CIVB
RIGL
RIGL
Q1 26
31.7%
Q4 25
384.0%
Q3 25
28.9%
40.2%
Q2 25
26.6%
58.6%
Q1 25
25.0%
21.5%
Q4 24
24.9%
Q3 24
21.3%
22.5%
Q2 24
18.5%
-2.8%
EPS (diluted)
CIVB
CIVB
RIGL
RIGL
Q1 26
$0.72
Q4 25
$0.59
$14.11
Q3 25
$0.68
$1.46
Q2 25
$0.71
$3.28
Q1 25
$0.66
$0.63
Q4 24
$0.62
$0.82
Q3 24
$0.53
$0.70
Q2 24
$0.45
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CIVB
CIVB
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$155.0M
Total DebtLower is stronger
$52.5M
Stockholders' EquityBook value
$553.9M
$391.5M
Total Assets
$4.3B
$513.6M
Debt / EquityLower = less leverage
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CIVB
CIVB
RIGL
RIGL
Q1 26
Q4 25
$155.0M
Q3 25
$137.1M
Q2 25
$108.4M
Q1 25
$77.1M
Q4 24
$77.3M
Q3 24
$61.1M
Q2 24
$49.1M
Total Debt
CIVB
CIVB
RIGL
RIGL
Q1 26
Q4 25
$52.5M
Q3 25
$60.0M
Q2 25
$60.0M
Q1 25
$60.0M
Q4 24
$60.0M
Q3 24
$60.0M
Q2 24
$60.0M
Stockholders' Equity
CIVB
CIVB
RIGL
RIGL
Q1 26
$553.9M
Q4 25
$543.5M
$391.5M
Q3 25
$499.0M
$117.6M
Q2 25
$404.1M
$81.9M
Q1 25
$397.4M
$18.6M
Q4 24
$388.5M
$3.3M
Q3 24
$394.4M
$-14.6M
Q2 24
$373.8M
$-29.9M
Total Assets
CIVB
CIVB
RIGL
RIGL
Q1 26
$4.3B
Q4 25
$4.3B
$513.6M
Q3 25
$4.1B
$242.5M
Q2 25
$4.2B
$206.7M
Q1 25
$4.1B
$176.0M
Q4 24
$4.1B
$164.0M
Q3 24
$4.1B
$139.4M
Q2 24
$4.0B
$128.4M
Debt / Equity
CIVB
CIVB
RIGL
RIGL
Q1 26
Q4 25
0.13×
Q3 25
0.51×
Q2 25
0.73×
Q1 25
3.23×
Q4 24
18.25×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CIVB
CIVB
RIGL
RIGL
Operating Cash FlowLast quarter
$22.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CIVB
CIVB
RIGL
RIGL
Q1 26
Q4 25
$43.3M
$22.0M
Q3 25
$19.0M
$24.0M
Q2 25
$11.1M
$30.5M
Q1 25
$3.6M
$-893.0K
Q4 24
$48.2M
$14.5M
Q3 24
$12.9M
$21.7M
Q2 24
$12.2M
$302.0K
Free Cash Flow
CIVB
CIVB
RIGL
RIGL
Q1 26
Q4 25
$42.1M
Q3 25
Q2 25
Q1 25
$3.5M
Q4 24
$44.1M
Q3 24
Q2 24
FCF Margin
CIVB
CIVB
RIGL
RIGL
Q1 26
Q4 25
90.9%
Q3 25
Q2 25
Q1 25
8.5%
Q4 24
109.1%
Q3 24
Q2 24
Capex Intensity
CIVB
CIVB
RIGL
RIGL
Q1 26
Q4 25
2.5%
Q3 25
Q2 25
Q1 25
0.4%
Q4 24
10.4%
Q3 24
Q2 24
Cash Conversion
CIVB
CIVB
RIGL
RIGL
Q1 26
Q4 25
0.08×
Q3 25
1.49×
0.86×
Q2 25
1.01×
0.51×
Q1 25
0.36×
-0.08×
Q4 24
1.01×
Q3 24
1.54×
1.75×
Q2 24
1.73×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CIVB
CIVB

Net Interest Income$37.8M80%
Noninterest Income$9.4M20%

RIGL
RIGL

Segment breakdown not available.

Related Comparisons